Apple
AAPL
Taylor Morrison Home
TMHC
D.R. Horton
DHI
Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
US Stock MarketDetailed Quotes
MIRM Mirum Pharmaceuticals
- 46.080
- -0.200-0.43%
Close Mar 27 16:00 ET
- 46.080
- 0.0000.00%
Post 16:24 ET
2.26BMarket Cap-24.91P/E (TTM)
47.170High45.610Low535.43KVolume46.800Open46.280Pre Close24.82MTurnover1.38%Turnover RatioLossP/E (Static)49.01MShares54.23452wk High10.01P/B1.79BFloat Cap23.14052wk Low--Dividend TTM38.86MShs Float54.234Historical High--Div YieldTTM3.37%Amplitude6.513Historical Low46.356Avg Price1Lot Size
About Mirum Pharmaceuticals Company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
Company Profile
SymbolMIRM
Company NameMirum Pharmaceuticals
Listing DateJul 18, 2019
Issue Price15.00
Founded2018
CEOMr. Christopher Peetz
MarketNASDAQ
Employees322
Fiscal Year Ends12-31
Address989 East Hillsdale Boulevard,Suite 300
CityFoster City
ProvinceCalifornia
CountryUnited States of America
Zip Code94404
Phone1-650-667-4085
Websitehttp://www.mirumpharma.com
Company Executives
- Name
- Position
- Salary
- Christopher Peetz
- Director and Chief Executive Officer
- 6.45M
- Peter Radovich
- Chief Operating Officer and President
- 2.37M
- Lara Longpre, PhD
- Chief Development Officer
- --
- Dr. Pamela Vig, PhD
- Chief Scientific Officer
- --
- Dr. Joanne Quan, M.D.
- Chief Medical Officer
- --
- Eric H. Bjerkholt
- Chief Financial Officer
- 4.34M
- Jody Howe
- Senior Vice President, Global Controller and Principal Accounting Officer
- --
- Michael Grey
- Chairman of the Board
- 451.75K
- Saira Ramasastry, M.Phil,M.S.
- Independent Director
- 411.75K
- Laura A. Brege
- Independent Director
- 426.75K
- William Carl Fairey, Jr
- Independent Director
- 411.75K
- Timothy P. Walbert
- Independent Director
- 671.53K
- Patrick J. Heron
- Independent Director
- 401.75K
- Dr. Lon Cardon, PhD
- Independent Director
- 194.47K
- Dr. Laurent Fischer, M.D.
- Independent Director
- 421.75K
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.